Pancreatic Calcification on Plain Abdominal X-ray in Chronic Pancreatitis

What is seen?

• Multiple discrete, punctate or coarse radiopaque densities located across the upper abdomen
• Distributed transversely across the midline, following the anatomical course of the pancreatic head, body, and tail
• Often described as a "chain-like" or stippled pattern at the L1–L2 vertebral level

• Intraductal calculi (stones within the main pancreatic duct — true intraductal calcification)
• Parenchymal calcification (calcium deposits in the pancreatic parenchyma)

Clinical Significance

• The presence of pancreatic calcification on plain X-ray is highly suggestive of chronic pancreatitis, particularly chronic alcohol-related pancreatitis
• It indicates advanced/late-stage disease with long-standing inflammation and fibrosis
• It is considered one of the most specific plain radiographic findings for chronic pancreatitis
• In the CT era, a combination of parenchymal calcifications + intraductal calcification + parenchymal atrophy + cystic lesions (≥3 of 4) allows diagnosis with high specificity

Differentiating from Other Calcifications

Radiographic Images

Erect plain abdominal X-ray showing multiple discrete punctate radiopaque densities distributed horizontally across the pancreatic bed — classic for chronic pancreatitis intraductal calculi

Extensive pancreatic calcifications spanning head, body, and tail — high specificity for chronic pancreatitis with exocrine and endocrine insufficiency

Coarse "chunky" intraductal calcifications following the main pancreatic duct — pathognomonic for chronic calcific pancreatitis (pancreatolithiasis)

Summary

Staging of Pancreatic Carcinoma

1. AJCC TNM Staging — provides prognostic grouping
2. NCCN Resectability-based Staging — guides surgical decision-making

1. AJCC TNM Staging (8th Edition)

T — Primary Tumour

Key change in 8th edition: T staging is now purely size-based for T1–T3. T4 is defined by arterial involvement (celiac, SMA, common hepatic artery), making it inherently unresectable.

N — Regional Lymph Nodes

Note: Nodal staging has limitations on imaging, as nodes can be involved without being enlarged.

M — Distant Metastasis

Stage Grouping

2. NCCN Resectability-based Classification

Resectable

Borderline Resectable

Locally Advanced (Unresectable)

SMA resection is not performed due to poor survival and high morbidity — hence >180° SMA involvement = unresectable.

Metastatic

• Evidence of spread to liver, peritoneum, or lung (most common sites)
• No surgical resection of primary tumour

Key Clinical Points

• Only ~15–20% of patients present with resectable disease at diagnosis
• Diagnostic laparoscopy identifies occult metastases in ~17% of patients who appear resectable on imaging — these are typically 1–2 mm liver/peritoneal lesions invisible on CT
• The "tear-drop deformity" of the SMV/PV on CT is a specific sign of venous infiltration
• Tumour–vessel contact > 180° circumference indicates vascular involvement; < 90° indicates low probability
• Splenic artery involvement is not T4 (it is resected with the pancreas in distal pancreatectomy)
• Pancreatic calcification with focal mass on CT should raise concern for coexisting cancer in chronic pancreatitis (up to 16-fold increased risk)

Investigations Used in Staging Pancreatic Carcinoma

1. Multidetector CT (MDCT) — Gold Standard

• Contrast-enhanced CT with pancreatic parenchymal + venous phase acquisition
• Thin-collimation, high-resolution slices
• Individualised bolus-tracking delay (aortic time + 25 seconds) is superior to a fixed 40-second delay
• 3D reconstructions using MPR, MIP, and VR to assess peripancreatic vasculature

• Predictive value for unresectability: 90–100%
• Predictive value for resectability: 76–90%
• Sensitivity for masses < 2 cm: ~77% (limitation)

• Focal MPD dilation with abrupt cut-off
• Upstream pancreatic atrophy
• Biliary obstruction
• Unusual pancreatic contour

2. Transabdominal Ultrasound (US)

• Usually the first investigation ordered (inexpensive, widely available)
• Highly accurate in differentiating obstructive vs. non-obstructive jaundice
• Can detect small tumours in the head with expertise
• NOT sufficient for staging — cannot assess extrapancreatic spread, vascular encasement, or peritoneal disease reliably
• Negative US does not rule out pancreatic cancer (especially body/tail tumours)

3. Endoscopic Ultrasound (EUS)

• Accuracy of 97.6% for diagnosing malignancy
• Key roles:
  • Biopsy of equivocal or non-obstructing lesions (EUS-guided FNA/FNB)
  • Defines anatomical relationship between tumour and peripancreatic vessels
  • Detects small tumours missed on CT (especially < 2 cm)
  • Assesses local nodal disease
• Particularly useful when CT is non-diagnostic or when tissue confirmation is needed before neoadjuvant therapy

4. MRI / MRCP

• Theoretical advantages over CT for small tumour detection and characterisation
• However, most studies show no significant advantage over MDCT in practice; less accessible and more costly
• MRCP is valuable for:
  • Detailed ductal anatomy (strictures, filling defects)
  • Excluding obstructing tumour when CT is ambiguous
• Gadolinium-enhanced MRI + DWI helps exclude malignancy as cause of ductal dilation when CT is equivocal
• If ERCP has been done (causing artefact/cholangitis), MRI can still assess the biliary system
• Uses identical vascular criteria to CT for resectability assessment

5. ERCP

• Still used for cytological sampling and biliary stent insertion in obstructive jaundice
• Limitation for staging: prior ERCP + stent insertion + cholangitis degrades the quality of subsequent MDCT/MRI, making detection of small tumours and assessment of longitudinal spread more difficult
• Therefore, "exploratory" ERCP without prior cross-sectional imaging should be avoided

6. Contrast-Enhanced Ultrasound (CEUS)

• High value for characterisation and differentiation of ductal adenocarcinoma from other pancreatic diseases
• Useful for cystic pancreatic lesions
• A recent meta-analysis confirmed its utility for distinguishing adenocarcinoma from chronic pancreatitis/focal masses

7. FDG PET/CT

• Limited role in initial staging
• Cannot reliably differentiate malignant from inflammatory pancreatic masses
• Low sensitivity for liver metastases
• Main current use: detection of local recurrence after treatment (high accuracy)

8. Diagnostic / Staging Laparoscopy

• Identifies occult metastases (liver/peritoneal) in ~17% of patients who appear resectable on imaging
• These are typically 1–2 mm implants below CT resolution
• Patients who avoid unnecessary laparotomy start palliative chemotherapy significantly earlier (17.9 vs. 39.9 days)
• Recommended in treatment-naïve patients before planned resection

Summary Table

Why Mesenteric Ischaemia?

Risk Factor Profile — Points Strongly to Vascular Disease

Classic Triad of Chronic Mesenteric Ischaemia

Why NOT the Other Options?

Key Distinguishing Feature

Weight loss WITH normal appetite is the hallmark of mesenteric ischaemia — the patient is hungry but afraid to eat because eating triggers pain (sitophobia). In gastric carcinoma, weight loss is accompanied by loss of appetite.

Diagnosis & Investigation

• Duplex Doppler USS — first-line screening (assesses celiac/SMA flow)
• CT angiography — investigation of choice to confirm stenosis/occlusion of celiac axis and SMA
• Digital subtraction angiography (DSA) — gold standard, also allows intervention

Treatment

• Endovascular stenting of the stenosed mesenteric vessels (preferred)
• Surgical revascularisation (bypass) in suitable candidates
• Optimise vascular risk factors (antiplatelet, statin, smoking cessation)